Foscarbidopa
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C10H15N2O7P |
Molar mass | 306.211 g·mol−1 |
3D model (JSmol) | |
| |
|
Foscarbidopa is a medication which acts as a prodrug for carbidopa. It is used in a subcutaneous infusion as a fixed-dose combination with foslevodopa for the treatment of Parkinson's disease, under the brand name Vyalev.[1][2]
References
[edit]- ^ Poplawska-Domaszewicz K, Batzu L, Falup-Pecurariu C, Chaudhuri KR (August 2024). "Subcutaneous Levodopa: A New Engine for the Vintage Molecule". Neurology and Therapy. 13 (4): 1055–1068. doi:10.1007/s40120-024-00635-4. PMC 11263521. PMID 38874708.
- ^ Fung VS, Aldred J, Arroyo MP, Bergquist F, Boon AJ, Bouchard M, et al. (2024). "Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance". Clinical Parkinsonism & Related Disorders. 10: 100239. doi:10.1016/j.prdoa.2024.100239. PMC 10900117. PMID 38419617.